In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporin

The in-vitro activity of BMY 28142, a new α-methoxyimino aminothiazolyl cephalosporin, was determined by microdilution broth techniques. The agent demonstrated excellent activity against recent clinical Enterobacteriaceae isolates with a 90% minimum inhibitory concentration (MIC₉₀) of 0·25 mg/l or less for all but one species tested. BMY 28142 inhibited all Pseudomonas aeruginosa strains tested (MIC₉₀=8·0 mg/l) as well as most other non-fermentative bacteria studied. Methicillin-susceptible Staphylococcus aureus were susceptible to BMY 28142 with MIC₉₀=4·0 mg/l, while methicillin-resistant strains were generally resistant (MIC range 8->32 mg/l).